Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS‐R)
Sign Up to like & getrecommendations! Published in 2017 at "American Journal of Hematology"
DOI: 10.1002/ajh.24732
Abstract: The Revised International Prognostic Scoring System (IPSS‐R) has been recognized as the score with the best outcome prediction capability in MDS, but this brought new concerns about the accurate prognostication of patients classified into the… read more here.
Keywords: category; risk; outcome prediction; mds ... See more keywords
The detection of circulating plasma cells may improve the Revised International Staging System (R‐ISS) risk stratification of patients with newly diagnosed multiple myeloma
Sign Up to like & getrecommendations! Published in 2021 at "British Journal of Haematology"
DOI: 10.1111/bjh.17118
Abstract: The Revised International Staging System (R‐ISS) stratifies patients affected by Multiple Myeloma (MM) into three distinct risk groups: R‐ISS I [ISS Stage I, Standard‐Risk cytogenetics and normal Lactase DeHydrogenase (LDH)], R‐ISS III (ISS stage III… read more here.
Keywords: risk; detection; staging system; system iss ... See more keywords
The impact of clonal size on the revised international prognostic scoring system (R-IPSS) in myelodysplastic syndromes (MDS) with a single cytogenetic abnormality.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.7068
Abstract: 7068Background: Cytogenetics is the backbone of the R-IPSS for MDS, contributing the most points (0 to 4) to the total scoring system. The current R-IPSS cytogenetics does not factor in the clone s... read more here.
Keywords: size revised; system; scoring system; impact clonal ... See more keywords